首页> 外文期刊>Drug Metabolism and Disposition: The Biological Fate of Chemicals >Effect of Endocannabinoid Oleamide on Rat and Human Liver Cytochrome P450 Enzymes in In Vitro and In Vivo Models
【24h】

Effect of Endocannabinoid Oleamide on Rat and Human Liver Cytochrome P450 Enzymes in In Vitro and In Vivo Models

机译:内胆碱解放于体外和体内模型大鼠大鼠和人肝细胞色素P450酶的影响

获取原文
获取原文并翻译 | 示例
           

摘要

The endocannabinoid system is important for many physiologic and pathologic processes, but its role in the regulation of liver cytochromes P450 (P450s) remains unknown. We studied the influence of the endocannabinoid oleamide on rat and human liver P450s. Oleamide was administered intraperitoneally to rats at doses of 0.1, 1, and 10 mg/kg per day for 7 days. The content and activity of key P450s were evaluated in rat liver microsomes. Moreover, interactions with nuclear receptors regulating P450 genes and serum levels of their ligands (prolactin, corticosterone, and free triiodothyronine) were tested in in vitro P450 inhibition assays. Decreased protein levels and metabolic activities of CYP1A2, CYP2B, and CYP2C11, along with a drop in metabolic activity of CYP2D2, were observed in animals treated with oleamide (10 mg/kg per day). The activities of CYP2C6, CYP2A, and CYP3A and the levels of hormones were not altered. In vitro, oleamide exhibited a weak inhibition of rat CYP1A2, CYP2D2, and CYP2C6. The activities of rat CYP2A, CYP2B, CYP2C11, and CYP3A and human CYP1A2, CYP2B6, CYP2C9, and CYP3A4 were not altered. Oleamide did not interact with human pregnane X, constitutive androstane, or aryl hydrocarbon receptors in reporter gene experiments and did not regulate their target P450 genes in primary human hepatocytes. Our results indicate that oleamide caused the downregulation of some rat liver P450s, and hormones are not mediators of this effect. In vitro oleamide inhibits mainly rat CYP2C6 and is neither an agonist nor antagonist of major human nuclear receptors involved in the regulation of xenobiotic metabolism.
机译:Endocannabinoid系统对于许多生理和病理过程很重要,但其在调节肝细胞色素P450(P450S)中的作用仍然未知。我们研究了Endocannabinoid Oleamide对大鼠和人肝P450s的影响。胃酰胺基于0.1,1和10mg / kg /天每天腹膜内的大鼠施用7天。在大鼠肝微粒体中评估关键P450s的含量和活性。此外,在体外P450抑制测定中测试与调节P450基因的核受体和它们配体的血清水平(催乳素,皮质酮和游离三碘噻吩)的相互作用。 CYP1A2,CYP2B和CYP2C11的蛋白质水平和代谢活性在用烯酰胺(每天10mg / kg)处理的动物中观察到CYP2D2的CYP2D2的代谢活性下降。 CYP2C6,CYP2A和CYP3A的活动和激素水平未被改变。体外,烯胺显示大鼠CYP1A2,CYP2D2和CYP2C6的弱抑制。大鼠CYP2A,CYP2B,CYP2C11和CYP3A和人CYP1A2,CYP2B6,CYP2C9和CYP3A4的活性未被改变。 Oleamide没有与人妊娠X,组成型和甲烷或芳基烃受体中的与报道基因实验中的芳基烃受体相互作用,并且在原发性人肝细胞中没有调节其靶P450基因。我们的结果表明,烯美酰胺引起了一些大鼠肝P450s的下调,并且激素不是这种效果的介质。体外烯烃主要抑制大鼠CYP2C6,并且既不是涉及异丙酚代谢调节的主要人体核受体的激动剂也不是拮抗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号